György Kéri | Academic Influence

György Kéri's AcademicInfluence.com Rankings

György Kéri

Biology

#12645

World Rank

#16136

Historical Rank

Biochemistry

#2519

World Rank

#2681

Historical Rank

biology Degrees

Download Badge

Biology

György Kéri's Degrees

PhD Biochemistry Semmelweis University
Doctorate Medicine Semmelweis University

Why Is György Kéri Influential?

(Suggest an Edit or Addition)

According to Wikipedia, György Kéri was a Hungarian biochemist, professor and Doctor of Biological Sciences . His major field of research was signal transduction therapy and he participated in the development of novel drug discovery technologies and drug candidates that entered the clinical development process.

(See a Problem?)

György Kéri's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. (2008) (590)
High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. (2004) (344)
Large-scale Proteomics Analysis of the Human Kinome (2009) (296)
Cellular targets of gefitinib. (2005) (226)
Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). (2005) (224)
AXL is a potential target for therapeutic intervention in breast cancer progression. (2008) (214)
Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. (2002) (209)
Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death. (2007) (171)
Antiinflammatory and analgesic effects of somatostatin released from capsaicin-sensitive sensory nerve terminals in a Freund's adjuvant-induced chronic arthritis model in the rat. (2004) (162)
Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. (2004) (148)
Proteomics strategy for quantitative protein interaction profiling in cell extracts (2009) (142)
Signaling through RAS-RAF-MEK-ERK: from basics to bedside. (2007) (121)
Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes. (2015) (118)
Proteomics Analysis of Protein Kinases by Target Class-selective Prefractionation and Tandem Mass Spectrometry *S (2007) (109)
Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling. (2005) (106)
NADPH Oxidase 4 Is Expressed in Pulmonary Artery Adventitia and Contributes to Hypertensive Vascular Remodeling (2014) (105)
A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity. (1996) (95)
Acid-base profiling of imatinib (gleevec) and its fragments. (2005) (95)
Leads for antitubercular compounds from kinase inhibitor library screens. (2010) (92)
Anti‐inflammatory effect of synthetic somatostatin analogues in the rat (2001) (90)
Metformin Attenuates Palmitate-Induced Endoplasmic Reticulum Stress, Serine Phosphorylation of IRS-1 and Apoptosis in Rat Insulinoma Cells (2014) (82)
Estimation of volume of distribution in humans from high throughput HPLC-based measurements of human serum albumin binding and immobilized artificial membrane partitioning. (2006) (80)
The Inosine Monophosphate Dehydrogenase, GuaB2, Is a Vulnerable New Bactericidal Drug Target for Tuberculosis (2016) (78)
Anticytolytic screen identifies inhibitors of mycobacterial virulence protein secretion. (2014) (76)
A novel drug discovery concept for tuberculosis: inhibition of bacterial and host cell signalling. (2008) (75)
Local Inhibition of Liver Fibrosis by Specific Delivery of a Platelet-Derived Growth Factor Kinase Inhibitor to Hepatic Stellate Cells (2007) (74)
Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance. (2012) (64)
Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry. (2008) (60)
Connective tissue growth factor is a new ligand of epidermal growth factor receptor. (2013) (59)
Anti-nociceptive effect induced by somatostatin released from sensory nerve terminals and by synthetic somatostatin analogues in the rat (2000) (59)
Pharmacological characterisation of the somatostatin analogue TT-232: effects on neurogenic and non-neurogenic inflammation and neuropathic hyperalgesia (2002) (59)
Small-molecule inhibitors of NADPH oxidase 4. (2010) (58)
Nanoparticles based on PLGA:poloxamer blends for the delivery of proangiogenic growth factors. (2010) (57)
Integrating molecular diagnostics into anticancer drug discovery (2010) (54)
TP53 mutation‐correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53‐mutated breast cancers (2014) (54)
Delivery of the p38 MAPkinase inhibitor SB202190 to angiogenic endothelial cells: development of novel RGD-equipped and PEGylated drug-albumin conjugates using platinum(II)-based drug linker technology. (2006) (54)
How Förster resonance energy transfer imaging improves the understanding of protein interaction networks in cancer biology. (2011) (53)
Gremlin regulates renal inflammation via the vascular endothelial growth factor receptor 2 pathway (2015) (53)
The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients (2009) (52)
Synthesis and evaluation of phosphorus containing, specific CDK9/CycT1 inhibitors. (2014) (51)
TWEAK transactivation of the epidermal growth factor receptor mediates renal inflammation (2013) (51)
Analgesic effect of TT-232, a heptapeptide somatostatin analogue, in acute pain models of the rat and the mouse and in streptozotocin-induced diabetic mechanical allodynia. (2004) (50)
Signal transduction therapy with rationally designed kinase inhibitors (2006) (50)
Sugar amino acid containing somatostatin analogues that induce apoptosis in both drug-sensitive and multidrug-resistant tumor cells. (2001) (48)
Determination of human serum alpha1-acid glycoprotein and albumin binding of various marketed and preclinical kinase inhibitors. (2009) (47)
Desensitization of luteinizing hormone release in cultured pituitary cells by gonadotropin-releasing hormone (1983) (47)
Cytostatic, cytotoxic and protein tyrosine kinase inhibitory activity of ursolic acid in A431 human tumor cells. (2000) (46)
Inhibitory effects of synthetic somatostatin receptor subtype 4 agonists on acute and chronic airway inflammation and hyperreactivity in the mouse. (2008) (43)
Abl‐kinase‐sensitive levels of ERK5 and its intrinsic basal activity contribute to leukaemia cell survival (2005) (43)
Comparison of predictive ability of water solubility QSPR models generated by MLR, PLS and ANN methods. (2004) (41)
The antitumor somatostatin analogue TT-232 induces cell cycle arrest through PKCdelta and c-Src. (2001) (41)
Inhibition of c-Met with the specific small molecule tyrosine kinase inhibitor SU11274 decreases growth and metastasis formation of experimental human melanoma. (2010) (40)
Rational Design of RGD–Albumin Conjugates for Targeted Delivery of the VEGF‐R Kinase Inhibitor PTK787 to Angiogenic Endothelium (2006) (40)
Co-clustering of Fcgamma and B cell receptors induces dephosphorylation of the Grb2-associated binder 1 docking protein. (2001) (39)
Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma (2017) (38)
Novel lipoamino acid- and liposaccharide-based system for peptide delivery: application for oral administration of tumor-selective somatostatin analogues. (1999) (37)
Physical and Functional Interactions between Protein Tyrosine Phosphatase α, PI 3-Kinase, and PKCδ (2001) (37)
Anti-apoptotic and apoptotic action of (2)-deprenyl and its metabolites (2001) (35)
Novel somatostatin analogs with tyrosine kinase inhibitory and antitumor activity. (1993) (35)
The Inflammatory Kinase MAP4K4 Promotes Reactivation of Kaposi's Sarcoma Herpesvirus and Enhances the Invasiveness of Infected Endothelial Cells (2013) (35)
Quantitative analysis of kinase-proximal signaling in lipopolysaccharide-induced innate immune response. (2010) (35)
A closer look at the structure of sterically stabilized liposomes: a small-angle X-ray scattering study. (2010) (33)
Plant-derived protein tyrosine kinase inhibitors as anticancer agents. (2004) (33)
Relationship between lipophilicity and antitumor activity of molecule library of Mannich ketones determined by high-performance liquid chromatography, clogP calculation and cytotoxicity test. (2002) (32)
Activation of caspase-3 protease during the process of ursolic acid and its derivative-induced apoptosis. (2001) (32)
Drug discovery in the kinase inhibitory field using the Nested Chemical Library technology. (2005) (32)
Multidrug Transporter ABCG 2 Prevents Tumor Cell Death Induced by the Epidermal Growth Factor Receptor Inhibitor Iressa ( ZD 1839 , Gefitinib ) (2005) (31)
An Integrated Phosphoproteomics Work Flow Reveals Extensive Network Regulation in Early Lysophosphatidic Acid Signaling* (2010) (31)
Improved, high yield synthesis of 3H-quinazolin-4-ones, the key intermediates of recently developed drugs. (2004) (31)
Structure-activity relationship studies of novel somatostatin analogs with antitumor activity. (1993) (31)
Molecular Pathomechanisms and New Trends in Drug Research (2007) (29)
Synthesis of selective SRPK-1 inhibitors: novel tricyclic quinoxaline derivatives. (2005) (29)
Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells (2012) (29)
The somatostatin analogue TT-232 induces apoptosis in A431 cells: sustained activation of stress-activated kinases and inhibition of signalling to extracellular signal-regulated kinases. (2001) (28)
Doxorubicin-induced activation of protein kinase D1 through caspase-mediated proteolytic cleavage: identification of two cleavage sites by microsequencing. (2004) (28)
Proteomics analysis of cellular imatinib targets and their candidate downstream effectors. (2010) (28)
Apoptosis is induced in both drug-sensitive and multidrug-resistant hepatoma cells by somatostatin analogue TT-232 (1999) (28)
Capillary Electrophoretic Analysis of Somatostatin Analog Peptides. Effect of Organic Solvents as Buffer Modifiers (1992) (27)
Lead selection and characterization of antitubercular compounds using the Nested Chemical Library. (2015) (27)
Tyrosine kinase inhibitors - small molecular weight compounds inhibiting EGFR. (2009) (26)
Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy. (2014) (25)
Design and synthesis of new imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives with antiproliferative activity against melanoma cells. (2016) (25)
Comparison of high-performance liquid chromatography and capillary electrophoresis in the analysis of somatostatin analogue peptides. (1993) (24)
Evaluation of lipophilicity and antitumour activity of parallel carboxamide libraries. (2002) (24)
Characterization of lipophilicity and antiproliferative activity of E-2-arylmethylene-1-tetralones and their heteroanalogues. (2005) (23)
Development of a 3D Tissue Culture–Based High-Content Screening Platform That Uses Phenotypic Profiling to Discriminate Selective Inhibitors of Receptor Tyrosine Kinases (2016) (23)
Tyrphostin induces non‐apoptotic programmed cell death in colon tumor cells (1995) (22)
The challenges of integrating molecular imaging into the optimization of cancer therapy. (2011) (21)
Comparison of measured and calculated lipophilicity of substituted aurones and related compounds. (2004) (21)
Identification of aminopyrimidine‐sulfonamides as potent modulators of Wag31‐mediated cell elongation in mycobacteria (2017) (20)
A somatostatin analogue induces translocation of Ku 86 autoantigen from the cytosol to the nucleus in colon tumour cells. (1998) (20)
TT-232: a somatostatin structural derivative as a potent antitumor drug candidate (2003) (19)
Development of a cell-selective and intrinsically active multikinase inhibitor bioconjugate. (2011) (19)
A novel plasmin-inhibitor inhibits the growth of human tumor xenografts and decreases metastasis number. (2002) (19)
Quantitative Phosphokinome Analysis of the Met Pathway Activated by the Invasin Internalin B from Listeria monocytogenes* (2009) (19)
Structure−Activity Relationship Studies Optimizing the Antiproliferative Activity of Novel Cyclic Somatostatin Analogues Containing a Restrained Cyclic β-Amino Acid† (2005) (18)
Machine learning and docking models for Mycobacterium tuberculosis topoisomerase I. (2017) (18)
Dendrimer-based macromolecular conjugate for the kidney-directed delivery of a multitargeted sunitinib analogue. (2012) (17)
Regulation of influenza a virus mRNA splicing by CLK1. (2019) (17)
Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers (2017) (17)
Effect of a novel somatostatin analogue combined with cytotoxic drugs on human tumour xenografts and metastasis of B16 melanoma (2003) (17)
N-Methylated sst2 Selective Somatostatin Cyclic Peptide Analogue as a Potent Candidate for Treating Neurogenic Inflammation. (2011) (17)
Evaluation of the antitumor efficacy of the somatostatin structural derivative TT-232 on different tumor models. (2006) (16)
Antiproliferative efficacy of the somatostatin analogue TT-232 in human melanoma cells and tumours. (2001) (15)
Conformational study of a series of somatostatin analogues with antitumor and/or GH inhibitory activity. (2009) (15)
The antitumor activity of the somatostatin structural derivative (TT-232) on different human tumor xenografts. (2003) (14)
The somatostatin analogue peptide TT-232 induces apoptosis and chromosome breakage in cultured human lymphocytes. (2000) (14)
Targeted drug combination therapy design based on driver genes (2019) (13)
Synthesis of somatostatin analogues containing C-terminal adamantane and their antiproliferative properties. (2008) (13)
Improved delivery of angiogenesis inhibitors from PLGA:poloxamer blend micro- and nanoparticles (2009) (13)
Determination of the basicity of Mannich ketones by capillary electrophoresis. (2004) (12)
Comparison of Elisa-Based Tyrosine Kinase Assays for Screening EGFR Inhibitors (2005) (12)
Decreased functional activity of multidrug resistance protein in primary colorectal cancer (2015) (12)
Chapter 6 Intracellular Delivery of the p 38 MAPK Inhibitor SB 202190 in Renal Tubular Cells : a Novel Strategy to Treat Renal Fibrosis (2006) (12)
Influence of various administration routes on the antitumor efficacy ofTT-232, a novel somatostatin analog. (2000) (11)
Physical and functional interactions between protein tyrosine phosphatase alpha, PI 3-kinase, and PKCdelta. (2001) (11)
Lipophilicity and antiproliferative activity profiling of 2-benzylidencycloalkanones. (2007) (11)
Novel compounds reducing IRS-1 serine phosphorylation for treatment of diabetes. (2016) (10)
Modern treatment of lung cancer: case 1. Amplification and mutation of the epidermal growth factor receptor in metastatic lung cancer with remission from gefitinib. (2005) (10)
Synthesis, characterization and systematic comparison of FITC‐labelled GnRH‐I, ‐II and ‐III analogues on various tumour cells (2016) (10)
Development of plasmin and plasma kallikrein selective inhibitors and their effect on M1 (melanoma) and HT29 cell lines. (2000) (9)
Small molecule somatostatin receptor subtype 4 (sst4) agonists are novel anti-inflammatory and analgesic drug candidates (2020) (9)
Binding crevice for TT-232 in a homology model of type 1 somatostatin receptor. (2004) (9)
Micellar electrokinetic chromatography of highly hydrophobic peptides (1998) (9)
Protein kinase inhibitor as a potential candidate for epilepsy treatment (2011) (9)
Comparison of the cytotoxic effects of receptor tyrosine kinase inhibitors on macrophage functions; possible side effects in the immune defense. (2006) (8)
Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors. (2014) (8)
Growth inhibitory effect of the somatostatin structural derivative (TT-232) on leukemia models. (2005) (8)
Targeting Vascular Endothelial Growth Factor Receptor 2 and Protein Kinase D1 Related Pathways by a Multiple Kinase Inhibitor in Angiogenesis and Inflammation Related Processes In Vitro (2015) (8)
Optimization of important early ADME(T) parameters of NADPH oxidase-4 inhibitor molecules. (2012) (8)
Continuous administration of the somatostatin structural derivative /TT-232/ by subcutaneously implanted osmotic pump improves the efficacy and potency of antitumor therapy in different mouse and human tumor models. (2008) (8)
Antitumor activity of the somatostatin structural derivative (TT-232), against mouse and human melanoma tumor models. (2007) (8)
Novel somatostatin analogs with antitumor activity (1993) (8)
In vivo antitumor activity of TT-232 a novel somatostatin analog. (1999) (8)
Pro‐Apoptotic and Anti‐Apoptotic Molecules Affecting Pathways of Signal Transduction (2003) (7)
A comparison of the tumor growth inhibitory effect of intermittent and continuous administration of the somatostatin structural derivative TT-232 in various human tumor models. (2006) (7)
A novel normalized retention factor in micellar electrokinetic chromatography (1999) (7)
Biodegradation of Luteinizing Hormone-Releasing Hormone (1982) (7)
Validation subset selections for extrapolation oriented QSPAR models (2004) (7)
Comparative characterization of experimental and calculated lipophilicity and anti-tumour activity of isochromanone derivatives. (2010) (7)
EVALUATION OF HYDROPHOBICITY AND ANTITUMOR ACTIVITY OF A MOLECULE LIBRARY OF MANNICH KETONES OF CYCLOALKANONES (2002) (7)
The antitumour effect of the somatostatin analogue TT-232 depends on the treatment regimen. (2003) (6)
Antitumour activity of folligen, a novel gonadotropin-releasing hormone analogue against DMBA-induced tumours in the rat. (1992) (6)
Analysis of macromolecular branched chain polypeptides by capillary electrophoresis and micellar electrokinetic chromatography (1996) (6)
New cyclic somatostatin analogues containing a pyrazinone ring: importance of Tyr for antiproliferative activity. (2008) (6)
Intracellular Delivery of the P38 MAPK Inhibitor SB202190 in Renal Tubular Cells: a Novel Strategy to Treat Renal Fibrosis (2006) (6)
Separation of anti‐tumor peptides by capillary electrophoresis in organic solvent containing background electrolytes (2003) (6)
Functional evaluation of multidrug resistance transporter activity in surgical samples of solid tumors. (2007) (6)
Design and synthesis of novel type somatostatin analogs with antiproliferative activities on A431 tumor cells (2004) (5)
Synthesis and biological evaluation of novel pyrido[2,3-b]pyrazines inhibiting both erlotinib-sensitive and erlotinib-resistant cell lines. (2013) (5)
Biochemical assay-based selectivity profiling of clinically relevant kinase inhibitors on mutant forms of EGF receptor. (2008) (5)
New antitumor leads from a peptidomimetic library (1999) (5)
Binding of a radiolabeled tumor selective GnRH analog to PC-3 human prostate cancer cells and the induction of apoptosis (1994) (4)
Investigation of the chemical stability of (d-Phe6, Gln8) GnRH (1–9)-ethylamide (Folligen) by high-performance liquid chromatography (1991) (4)
Comparative analysis of somatostatin analog peptides by capillary electrophoresis and micellar elektrokinetic chromatography (1996) (4)
Screening for MAPK modulators using an in-cell western assay. (2014) (4)
Local inhibition of liver fi brosis by specifi c delivery of a PDGF kinase inhibitor to hepatic stellate cells (2006) (4)
Binding specificity of the l-arginine transport systems in mouse macrophages and human cells overexpressing the cationic amino acid transporter hCAT-1 (2009) (4)
Synthesis and characterization of novel quinazoline type inhibitors for mutant and wild-type EGFR and RICK kinases. (2008) (4)
Detection of hydrogen peroxide by lactoperoxidase-mediated dityrosine formation (2009) (4)
Biochemical Assay-Based Selectivity Profiling of Clinically Relevant Kinase Inhibitors on Mutant Forms of EGF Receptor (2008) (4)
Synthesis and Characterization of Novel Quinazoline Type Inhibitors for Mutant and Wild-Type EGFR and RICK Kinases (2008) (3)
network regulation in early lysophosphatidic acid signaling (2010) (3)
Analysis of polyanionic macromolecular carrier poly‐(N‐vinylpyrrolidone‐co‐maleic acid) and its bioconjugates by capillary electrophoresis (1998) (3)
Comparison of the binding modes of TT-232 in somatostatin receptors type 1 and 4 (2007) (3)
Rational Drug Design of Kinase Inhibitors for Signal Transduction Therapy (2011) (3)
[Pyrido[2,3-b]pyrazines inhibiting both erlotinib-sensitive and erlotinib-resistant cell lines, and their preparation via regioselective condensation reaction]. (2014) (3)
TT-232: An Anti-tumour and Anti-inflammatory Peptide Therapeutic in Clinical Development (2005) (3)
A specifically radiolabeled somatostatin analog with strong antitumor activity induces apoptosis and accumulates in the cytosol and the nucleus of HT29 human colon carcinoma cells (1999) (2)
Novel antitumor peptide hormones and their effect on signal transduction (1992) (2)
[Epidermal growth factor receptor (EGFR): therapeutic target in the treatment of lung adenocarcinoma]. (2005) (2)
Cancer as a communication disorder (2002) (2)
Correction: Targeting Vascular Endothelial Growth Factor Receptor 2 and Protein Kinase D1 Related Pathways by a Multiple Kinase Inhibitor in Angiogenesis and Inflammation Related Processes In Vitro (2015) (2)
Preparation of Pyrido[2,3-b]pyrazine Ring System via Regioselective Condensation Reaction (2014) (2)
Molecular Pathomechanisms and New Trends in Drug Design (2003) (2)
New antitumor leads from a peptidomimetic library (2004) (2)
Synthesis of GnRH analogs having direct antitumor and low LH-releasing activity. (1996) (2)
Specific targeting of a PDGFR tyrosine kinase inhibitor to activated hepatic stellate cells as a promising technology to reduce liver fibrosis (2005) (2)
Antitumor activity and pharmacology of TT-232 (a novel somatostatin structural derivative) in malignant melanoma patients. (2004) (2)
Micellar proportion: A parameter to compare the hydrophobicity of the pseudostationary phases or that of the analytes in micellar electrokinetic chromatography (2005) (2)
Identification of Protein Kinase Inhibitors with a Selective Negative Effect on the Viability of Epstein-Barr Virus Infected B Cell Lines (2014) (2)
[Developing FGFR inhibitors as potential anti-cancer agents]. (2013) (2)
Kinase Inhibitors in Signal Transduction Therapy (2011) (2)
Mechanisms and targets of glomerular damage (2012) (1)
Novel lipoamino acid and liposaccharide based peptide delivery system for tumor selective somatostatin analogs (2000) (1)
M 2 Induces Programmed Cell Death Nuclear Translocation of the Tumor Marker Pyruvate Kinase Updated (2007) (1)
992 Human phase II/A study of a novel somatostatin analogue, TT-232 in malignant melanoma patients (2003) (1)
XIXth Meeting of the International Society for Oncodevelopment Biology and Medicine, Siena, October 13–17, 1991 (Part 1 of 4) (1992) (1)
[Application of Kohonen Self-Organizing Feature Maps in QSAR of human ADMET and kinase data sets]. (2013) (1)
New Method for the Synthesis of 2-Acylamino-1-benzothiophene-3-carboxamide Derivatives from the Corresponding Esters (2008) (1)
Functional assessment of multidrug resistance in colorectal, pancreatic and liver malignancies (2005) (1)
Tritium Labeling of Brain Peptides (1982) (1)
Proteomic analysis of protein kinases by target class- selective pre-fractionation and tandem mass spectrometry (2008) (1)
Antiproliferative and apoptosis-inducing effect of a new Somatostatin analogue (TT-232) (1997) (1)
CALCULATION OF PHASE RESIDENCE TIMES IN MICELLAR ELECTROKINETIC CHROMATOGRAPHY (2001) (1)
[Development and biochemical characterization of EGFR/c-Met dual inhibitors]. (2013) (1)
Protein kinase inhibitor-induced endothelial cell cytotoxicity and its prediction based on calculated molecular descriptors (2009) (1)
Novel antitumor peptides and their mechanism of action (1991) (1)
Effect of New Synthetic Peptides and Peptidomimetics on Angiogenesis (2007) (1)
Population Pharmacogenomics and Personalized Medicine Research in Hungary: Achievements and Lessons Learned (2010) (1)
Gonadotropin Releasing Hormone and its Analogs Desensitize Pituitary GnRH Action (1983) (1)
Redox Control of the Critical Immune Regulatory Enzyme Indoleamine 2,3-Dioxygenase by NADPH Oxidase 2-Derived Reactive Oxygen Species in Human Monocytes (2016) (1)
Investigation of the chemical stability of a new growth hormone-releasing hormone (GHRH) analogue by HPLC. (1996) (1)
Preface breakthrough in cancer research: Personalized genomic medicine based signal transduction therapy of cancer addressing the driver genes (2015) (0)
Use of inhibitors of the platelet-fragments of muscles growth factor receptor for the manufacture of a lægmiddel to Behan (1995) (0)
A novel assay to test multidrug-resistance of mucosa-infiltrating and peripheral blood lymphocytes in patients with inflammatory bowel disease (IBD) (2004) (0)
P-966 Gefitinib treatment in brain metastasis of lung adenocarcinoma with EGFR amplification and mutation (case report) (2005) (0)
Effect of YO-2 (Plasmin Inhibitor) on the Growth of Human Tumor Xenografts in Mice (2001) (0)
Structure-activity relationship studies optimizing the antiproliferative activity of novel cyclic somatostatin analogues containing a restrained cyclic beta-amino acid. (2005) (0)
HPLC Analysis, Modeling, and Biological Studies of Antiproliferative Heterocyclic Carboxamides (2001) (0)
Octapeptide or heptapeptide derivatives, their preparation as well as medicaments containing them and their use. (1992) (0)
Conformationally restricted new somatostatin analogs (1995) (0)
SIGNAL TRANSDUCTION THERAPY OF TUMORS WITH MULTIPLE TARGET KINASE INHIBITORS (2008) (0)
New Method for the Synthesis of 2‐Acylamino‐1‐benzothiophene‐3‐carboxamide Derivatives from the Corresponding Esters. (2009) (0)
New Antiproliferative Agents from a Peptidomimetic Library (2001) (0)
XIXth Meeting of the International Society for Oncodevelopment Biology and Medicine, Siena, October 13–17, 1991 (Part 4 of 4) (1992) (0)
Characterization of p53 activator compounds which inhibit a survival factor kinase as well (2012) (0)
Method for obtaining genital mammal products suitable for natural and artificial fertilization (1986) (0)
[Development and study of structure-activity relationship of drugs against Mycobacterium tuberculosis]. (2013) (0)
Screening of peptidomimetic libraries for antitumor activity (2000) (0)
New somatostatin analogs with selective biological activity (1993) (0)
Method for obtaining loans sexual fertilization products from sexually mature fish (1984) (0)
Lipoamino acid and glycolipid conjugated peptides enhanced intestinal absorption of an anti-tumour somatostatin analogue (2000) (0)
Utilization receptor inhibitors mitogenic growth factor platelet for making a medicament for the treatment of cancer. (1995) (0)
Signal transduction therapy of colon tumors with multiple target kinase inhibitors (2009) (0)
Synthetic lethality screens of vichem compounds in P53 mutant syngenic cell line models (2008) (0)
The Antiproliferative Activities of Somatostatin Analogs on Various Tumor Cells (2006) (0)
Similarity-based automated evidence ranking for clinical interpretation of multigene diagnostic panels (2016) (0)
The effect of novel superactive GNRH analogs on LH release and on mammary tumors (1987) (0)
Peptidomimetic tyrosine kinase inhibitors induce non apoptotic, Clarke-III type programmed cell death (2002) (0)
Introduction: A breakthrough in modern drug research (2003) (0)
Signal transduction therapy of cancer with kinase inhibitors (2013) (0)
XIXth Meeting of the International Society for Oncodevelopment Biology and Medicine, Siena, October 13–17, 1991 (Part 2 of 4) (1992) (0)
Conformations of somatostatin analogues having antitumor activity (1993) (0)
Glycolipid-modified peptides: Enhancement of absorption of an anti-tumour somatostatin analogue (2000) (0)
[Synthesis of thiophene and alpha-terthiophene derivatives with antiproliferative activity]. (2005) (0)
Host cell signalling inhibitors against helicobacter pylori (2009) (0)
RECOMBINANT HUMAN EGFR PROTEIN-FRAGMENTS FOR SCREENING OF DRUG CANDIDATE COMPOUNDS TARGETING PANCREATIC CANCER. (2004) (0)
XIXth Meeting of the International Society for Oncodevelopment Biology and Medicine, Siena, October 13–17, 1991 (Part 3 of 4) (1992) (0)
Experimental models of CKD (2013) (0)
[Synthesis of 4-Chloro-6-(substituted-phenyl)-pyrimidines]. (2010) (0)
Use of inhibitors of the receptor of platelet-derived growth factors for preparing a medicament for the treatment of cancer (1995) (0)
Contents, Vol. 9, 1988 (1988) (0)
Driver-target-drug algorithm in the interpretation of molecular cancer profiles. (2015) (0)
Behaviour of macromolecular drug carrier poly(N-vinyl pyrrolidone-co- maleic acid) and its bioconjugates at different pH values investigated by gel permeation chromatography (1998) (0)
Process for obtaining sexual products from mammals (1986) (0)
Preparation of human EGFR intracellular domain-GST fusion protein with recombinant technique (2004) (0)
The use of somatostatin derivatives, and / or of phenylhydrazone derivatives (1999) (0)
Synthesis of Somatostatin Analogs and Their Antitumor Activities (2004) (0)
Current Signal Transduction Therapy: Preface (2011) (0)
CHARACTERIZATION OF NOVEL SPECIES SPECIFIC GnRH ANALOGS WHICH CAN BE USED FOR THE INDUCED ARTIFICIAL PROPAGATION OF FISHES (1987) (0)
Active Somatostatin Analogues Containing Sugar Amino Acids (2001) (0)
Mechanism of action of a tumor-selective somatostatin analog: TT-232 (1995) (0)
801: Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors − suggestion of combination therapy (2014) (0)
Activation of HER 3 Interferes with Antitumor Effects of Axl Receptor Tyrosine Kinase Inhibitors : Suggestion of Combination Therapy 1 (2014) (0)
Novel antitumor peptide hormones with selective antitumor activity (1994) (0)
Use of adult male bonnet monkeys (Macaca radiata) for testing the biological activity of gonadotropin releasing hormone and its analogues (2009) (0)
Further Studies of the Signaling Mechanisms of the Antitumor Somatostatin Analogue TT-232 (2001) (0)
Screening of peptidomimetic tyrosine kinase inhibitors for inducing programmed cell death (1999) (0)
PDGFR TK assay for screening inhibitory compound-libararies (2004) (0)
The antitumor somatostatin analog (TT232) induced signaling cascades (2000) (0)
Procedure for obtaining sexual products suitable for natural and artificial fertilization from mammals (1986) (0)
Alterations of MDR1 and MRP1 functional activity of colorectal malignancies in a prospective clinical trial (2008) (0)
Drug Discovery and Development in the Kinase Inhibitory Field with Nested Chemical Library TM (2007) (0)
Liposaccharide based peptide delivery system for tumour selective somatostatin analogues (2000) (0)
Process for the preparation of gonadoliberinos derivatives containing an aromatic acid in position 6 aminocarboxilio (1987) (0)
Use of polyunsaturated fatty acid derivatives in the preparation of medicaments with tyrosine kinase inhibiting activity (1990) (0)
Selectivity profiling and off-target identification of clinically relevant kinase inhibitors for gastrointestinal tumors (2008) (0)
Analysis of protein kinases by quantitative chemical proteomics (2007) (0)
[Novel method for the synthesis of carboxamides from low reactivity esters: synthesis of 2-acylamino-1-benzothiophene-3-carboxamides]. (2008) (0)
A novel lipoamino acid based system for peptide delivery: Application for administering tumor selective somatostatin analogues (2002) (0)

This paper list is powered by the following services:

Other Resources About György Kéri

en.wikipedia.org

What Schools Are Affiliated With György Kéri?

György Kéri is affiliated with the following schools:

Image Attributions

Image Source for György Kéri